Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[The enrichment of ERBB2 mutations/fusion in CDH1-mutated ILC (5 of 22, 23%) compared with the 5 ERBB2 mutations in a series of 286 non-CDH1-mutated breast cancers from which the ILC cases were obtained (5 of 286, 2%) was significant (P = 0.0006).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP258812.RAQKNwARPssjSQD7854AfeBtx0g9UTgAc1c-P81bR4FME130_assertion description "[The enrichment of ERBB2 mutations/fusion in CDH1-mutated ILC (5 of 22, 23%) compared with the 5 ERBB2 mutations in a series of 286 non-CDH1-mutated breast cancers from which the ILC cases were obtained (5 of 286, 2%) was significant (P = 0.0006).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP258812.RAQKNwARPssjSQD7854AfeBtx0g9UTgAc1c-P81bR4FME130_provenance.
• NP767701.RAmWkd8jytl-okpF4J_jTfj_q2k0rcEW-Ttvm8g6yE5VI130_assertion description "[The enrichment of ERBB2 mutations/fusion in CDH1-mutated ILC (5 of 22, 23%) compared with the 5 ERBB2 mutations in a series of 286 non-CDH1-mutated breast cancers from which the ILC cases were obtained (5 of 286, 2%) was significant (P = 0.0006).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP767701.RAmWkd8jytl-okpF4J_jTfj_q2k0rcEW-Ttvm8g6yE5VI130_provenance.
• assertion description "[The enrichment of ERBB2 mutations/fusion in CDH1-mutated ILC (5 of 22, 23%) compared with the 5 ERBB2 mutations in a series of 286 non-CDH1-mutated breast cancers from which the ILC cases were obtained (5 of 286, 2%) was significant (P = 0.0006).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The enrichment of ERBB2 mutations/fusion in CDH1-mutated ILC (5 of 22, 23%) compared with the 5 ERBB2 mutations in a series of 286 non-CDH1-mutated breast cancers from which the ILC cases were obtained (5 of 286, 2%) was significant (P = 0.0006).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP299279.RAd8mDb4i7YBT7K85_zAI_IOO9c_MUi37VSk3ic15iVFQ130_assertion description "[The enrichment of ERBB2 mutations/fusion in CDH1-mutated ILC (5 of 22, 23%) compared with the 5 ERBB2 mutations in a series of 286 non-CDH1-mutated breast cancers from which the ILC cases were obtained (5 of 286, 2%) was significant (P = 0.0006).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP299279.RAd8mDb4i7YBT7K85_zAI_IOO9c_MUi37VSk3ic15iVFQ130_provenance.
• NP904899.RAZlei4T3ShXKdwochGtgv8jaRFamRyT3ilVh-dc6KyWY130_assertion description "[The enrichment of ERBB2 mutations/fusion in CDH1-mutated ILC (5 of 22, 23%) compared with the 5 ERBB2 mutations in a series of 286 non-CDH1-mutated breast cancers from which the ILC cases were obtained (5 of 286, 2%) was significant (P = 0.0006).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP904899.RAZlei4T3ShXKdwochGtgv8jaRFamRyT3ilVh-dc6KyWY130_provenance.
• NP1068233.RATfVFIP9yubEEGLDmStO64FvGVX9YtQjFjPaxTzSCrBw130_assertion description "[The enrichment of ERBB2 mutations/fusion in CDH1-mutated ILC (5 of 22, 23%) compared with the 5 ERBB2 mutations in a series of 286 non-CDH1-mutated breast cancers from which the ILC cases were obtained (5 of 286, 2%) was significant (P = 0.0006).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1068233.RATfVFIP9yubEEGLDmStO64FvGVX9YtQjFjPaxTzSCrBw130_provenance.
• NP299568.RAtm8sM86DhcKzwpZdOx5E4FnErrLkjMOtmdS3bGUS8l8130_assertion description "[The enrichment of ERBB2 mutations/fusion in CDH1-mutated ILC (5 of 22, 23%) compared with the 5 ERBB2 mutations in a series of 286 non-CDH1-mutated breast cancers from which the ILC cases were obtained (5 of 286, 2%) was significant (P = 0.0006).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP299568.RAtm8sM86DhcKzwpZdOx5E4FnErrLkjMOtmdS3bGUS8l8130_provenance.
• NP1068230.RAlCixP7a0Ov8Ogsnxu3EWZqubfXFyvk0AqcZ9Lwwv78I130_assertion description "[The enrichment of ERBB2 mutations/fusion in CDH1-mutated ILC (5 of 22, 23%) compared with the 5 ERBB2 mutations in a series of 286 non-CDH1-mutated breast cancers from which the ILC cases were obtained (5 of 286, 2%) was significant (P = 0.0006).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1068230.RAlCixP7a0Ov8Ogsnxu3EWZqubfXFyvk0AqcZ9Lwwv78I130_provenance.
• NP1068234.RAJCYyJ83_1FtQnm5RLfOm0BIo24v6Y3KHCPll4DHqs0Y130_assertion description "[The enrichment of ERBB2 mutations/fusion in CDH1-mutated ILC (5 of 22, 23%) compared with the 5 ERBB2 mutations in a series of 286 non-CDH1-mutated breast cancers from which the ILC cases were obtained (5 of 286, 2%) was significant (P = 0.0006).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1068234.RAJCYyJ83_1FtQnm5RLfOm0BIo24v6Y3KHCPll4DHqs0Y130_provenance.
• NP1068231.RA5SqL-Bo4uTnuoJVAV_QyPU9SpKofxmSgB0styQEcZlg130_assertion description "[The enrichment of ERBB2 mutations/fusion in CDH1-mutated ILC (5 of 22, 23%) compared with the 5 ERBB2 mutations in a series of 286 non-CDH1-mutated breast cancers from which the ILC cases were obtained (5 of 286, 2%) was significant (P = 0.0006).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1068231.RA5SqL-Bo4uTnuoJVAV_QyPU9SpKofxmSgB0styQEcZlg130_provenance.
• NP1068237.RAyEtUNqMXhbC49F9pLwc8szR24efvwXl_rxbOTOFW0Vc130_assertion description "[The enrichment of ERBB2 mutations/fusion in CDH1-mutated ILC (5 of 22, 23%) compared with the 5 ERBB2 mutations in a series of 286 non-CDH1-mutated breast cancers from which the ILC cases were obtained (5 of 286, 2%) was significant (P = 0.0006).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1068237.RAyEtUNqMXhbC49F9pLwc8szR24efvwXl_rxbOTOFW0Vc130_provenance.
• NP904742.RA9UhF2WH1D5YkvBrvgSmVXGIDKZE-0NVlMQ276Om9C4s130_assertion description "[The enrichment of ERBB2 mutations/fusion in CDH1-mutated ILC (5 of 22, 23%) compared with the 5 ERBB2 mutations in a series of 286 non-CDH1-mutated breast cancers from which the ILC cases were obtained (5 of 286, 2%) was significant (P = 0.0006).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP904742.RA9UhF2WH1D5YkvBrvgSmVXGIDKZE-0NVlMQ276Om9C4s130_provenance.